LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 6 of 15: Mean cell count and mean growth rate across biological replicate 3. - Dataset (ID:20242)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
---|---|---|---|---|---|---|---|---|---|---|---|
MCF7 | PF431396 | 0.04 | uM | LJP5 | 72 | hr | 1209 | 3174 | 4093 | 0.7755 | 0.6813 |
MCF7 | PF477736 | 0.04 | uM | LJP5 | 72 | hr | 1209 | 2896 | 4093 | 0.7076 | 0.5849 |
MCF7 | PF562271 | 0.04 | uM | LJP6 | 72 | hr | 1209 | 3497 | 4093 | 0.8546 | 0.7935 |
MCF7 | PHA-665752 | 0.04 | uM | LJP5 | 72 | hr | 1209 | 4385 | 4093 | 1.0715 | 1.1015 |
MCF7 | PHA-793887 | 0.04 | uM | LJP6 | 72 | hr | 1209 | 1898 | 4093 | 0.4638 | 0.2389 |
MCF7 | PI103 | 0.04 | uM | LJP6 | 72 | hr | 1209 | 2628 | 4093 | 0.6422 | 0.4920 |
MCF7 | PLX-4720 | 0.04 | uM | LJP5 | 72 | hr | 1209 | 4027 | 4093 | 0.9839 | 0.9771 |
MCF7 | QL-X-138 | 0.04 | uM | LJP6 | 72 | hr | 1209 | 2945 | 4093 | 0.7196 | 0.6020 |
MCF7 | QL-XII-47 | 0.04 | uM | LJP6 | 72 | hr | 1209 | 2151 | 4093 | 0.5257 | 0.3267 |
MCF7 | Radicicol | 0.04 | uM | LJP5 | 72 | hr | 1209 | 2692 | 4093 | 0.6579 | 0.5144 |
MCF7 | Radicicol | 0.04 | uM | LJP6 | 72 | hr | 1209 | 2453 | 4093 | 0.5995 | 0.4315 |
MCF7 | Seliciclib | 0.04 | uM | LJP5 | 72 | hr | 1209 | 4445 | 4093 | 1.0860 | 1.1221 |
MCF7 | Ruxolitinib | 0.04 | uM | LJP5 | 72 | hr | 1209 | 4326 | 4093 | 1.0571 | 1.0810 |
MCF7 | XL147 | 0.04 | uM | LJP5 | 72 | hr | 1209 | 4436 | 4093 | 1.0840 | 1.1192 |
MCF7 | Saracatinib | 0.04 | uM | LJP6 | 72 | hr | 1209 | 3381 | 4093 | 0.8260 | 0.7531 |
MCF7 | Selumetinib | 0.04 | uM | LJP6 | 72 | hr | 1209 | 3122 | 4093 | 0.7629 | 0.6634 |
MCF7 | Sirolimus | 0.04 | uM | LJP6 | 72 | hr | 1209 | 2216 | 4093 | 0.5416 | 0.3493 |
MCF7 | Sorafenib | 0.04 | uM | LJP6 | 72 | hr | 1209 | 3745 | 4093 | 0.9150 | 0.8793 |
MCF7 | SU11274 | 0.04 | uM | LJP5 | 72 | hr | 1209 | 4485 | 4093 | 1.0959 | 1.1361 |
MCF7 | Fedratinib | 0.04 | uM | LJP5 | 72 | hr | 1209 | 4036 | 4093 | 0.9861 | 0.9802 |
MCF7 | TGX221 | 0.04 | uM | LJP5 | 72 | hr | 1209 | 3847 | 4093 | 0.9399 | 0.9147 |
MCF7 | Torin1 | 0.04 | uM | LJP6 | 72 | hr | 1209 | 1482 | 4093 | 0.3621 | 0.0945 |
MCF7 | Torin2 | 0.04 | uM | LJP5 | 72 | hr | 1209 | 1120 | 4093 | 0.2736 | -0.0311 |
MCF7 | Tozasertib | 0.04 | uM | LJP5 | 72 | hr | 1209 | 1353 | 4093 | 0.3307 | 0.0499 |
MCF7 | Trametinib | 0.04 | uM | LJP5 | 72 | hr | 1209 | 2188 | 4093 | 0.5347 | 0.3395 |